Ekaterina V. Kurbatova

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova et al. · New England Journal of Medicine · 2021 · 551 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020

Leah F. Moriarty, Mateusz M. Pluciński, Barbara J. Marston et al. · MMWR Morbidity and Mortality Weekly Report · 2020 · 430 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +14

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Tracy Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet · 2012 · 227 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

Ekaterina V. Kurbatova, J. Peter Cegielski, Christian Lienhardt et al. · The Lancet Respiratory Medicine · 2015 · 158 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects

Ekaterina V. Kurbatova, A. Taylor, Victoria M. Gammino et al. · Tuberculosis · 2012 · 154 citations · Full text

Public Health, Health Sciences, Infectious Diseases +16